PloS one · 2026
Contemporary patients with atrial fibrillation are not anticoagulated despite risks of stroke - Insights from GARDENIA.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kakkar A K, Bonaca Marc P, Giugliano Robert P, Pieper Karen, Bloomfield Dan, Hug Bruce, Salter Janeen, Freedholm Debra, Parkar Sanobar, Virdone Saverio, Prakasam Herman Sandeep, Fluharty Meg, Kayani Gloria, Fox Keith A A, GARDENIA investigators
Аннотация
BACKGROUND: GARDENIA is a global, multicentre, prospective, non-interventional study in high-risk atrial fibrillation (AF) patients, who were untreated with anticoagulants.
OBJECTIVES: Provide contemporary evidence on reasons for non-treatment with an anticoagulant, and outcomes in high-risk AF patients.
METHODS: GARDENIA enrolled 704 AF patients with a CHA2DS2-VA score ≥2 and an elevated risk of bleeding (older age (≥70 years), reduced renal function, concomitant antiplatelet or NSAID use, or other conditions associated with increased bleeding risk), and had not been recently treated with an oral anticoagulant (OAC). Patients were followed for at least 4 months. The two-year risks of mortality, stroke and major bleeding with or without direct OACs (DOACs) in these patients was estimated using the GARFIELD risk score.
RESULTS: History of major bleeding (18.7%), physician-assessed high-risk of bleeding (17.1%), and patient refusal (17.6%) were the top reasons for not initiating OACs. The 100-person-year event rates (95% CI) for mortality, stroke/systemic embolism (SE)/transient ischemic attack (TIA), and ISTH major bleeding were 13.22 (10.33, 16.92), 2.12 (1.14, 3.94), and 2.21 (1.13, 3.91), respectively. GARFIELD risk analysis indicated a 31% and 40% increase in the risk of mortality and stroke, respectively, and a ~ 30% decrease in risk of major bleeding, compared to the estimated risk, had the patients been anticoagulated. The study was prematurely terminated due to low rate of patient accrual.
CONCLUSIONS: Perceived risk of bleeding was the leading cause for non-treatment with OACs in high-risk AF patients. Risk prediction modelling indicated that the benefits of anticoagulation in stroke and mortality reduction outweigh the risk of bleeding.
OBJECTIVES: Provide contemporary evidence on reasons for non-treatment with an anticoagulant, and outcomes in high-risk AF patients.
METHODS: GARDENIA enrolled 704 AF patients with a CHA2DS2-VA score ≥2 and an elevated risk of bleeding (older age (≥70 years), reduced renal function, concomitant antiplatelet or NSAID use, or other conditions associated with increased bleeding risk), and had not been recently treated with an oral anticoagulant (OAC). Patients were followed for at least 4 months. The two-year risks of mortality, stroke and major bleeding with or without direct OACs (DOACs) in these patients was estimated using the GARFIELD risk score.
RESULTS: History of major bleeding (18.7%), physician-assessed high-risk of bleeding (17.1%), and patient refusal (17.6%) were the top reasons for not initiating OACs. The 100-person-year event rates (95% CI) for mortality, stroke/systemic embolism (SE)/transient ischemic attack (TIA), and ISTH major bleeding were 13.22 (10.33, 16.92), 2.12 (1.14, 3.94), and 2.21 (1.13, 3.91), respectively. GARFIELD risk analysis indicated a 31% and 40% increase in the risk of mortality and stroke, respectively, and a ~ 30% decrease in risk of major bleeding, compared to the estimated risk, had the patients been anticoagulated. The study was prematurely terminated due to low rate of patient accrual.
CONCLUSIONS: Perceived risk of bleeding was the leading cause for non-treatment with OACs in high-risk AF patients. Risk prediction modelling indicated that the benefits of anticoagulation in stroke and mortality reduction outweigh the risk of bleeding.